NONALCOHOLIC FATTY LIVER DISEASE
|
|
- Darleen Jennings
- 5 years ago
- Views:
Transcription
1 NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD, MSc Hepatology and Liver Transplantation University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Terminology Pathogenesis Epidemiology Prevalence Natural History Age/Race-Ethnicity Approach to the patient with suspected NAFLD Diagnosis/ Disease Severity Treatment NAFLD Alcohol-like liver disease in individuals who do not consume excessive alcohol Women 1 drink/day (on average) Men 2 drinks/day (on average) Fatty liver associated with metabolic derangements Obesity Insulin resistance Diabetes mellitus Dyslipidemia Hypertension Metabolic Syndrome
2 Non-Alcoholic Fatty Liver Disease NAFLD Pathogenesis
3 NAFLD Pathogenesis: Old, but still entrenched, Concept There is a linear progression in disease severity Simple Steatosis NASH Cirrhosis NAFLD Pathogenesis: Old, but still entrenched, Concept There is a linear progression in disease severity Simple Steatosis NASH Cirrhosis NAFLD Pathogenesis: Old, but still entrenched, Concept Day and James, Gastroenterology 1998
4 NAFLD Pathogenesis: Old, but still entrenched, Concept Day and James, Gastroenterology 1998 Lipotoxicity Model of Pathogenesis the cause of steatosis, and not the fat accumulation by itself, produces cirrhosis. - Heribert Thaler, 1975 Clin Gastro 1975;4: Hepatology 2010;52: Lipotoxicity Model of Pathogenesis the cause of steatosis, and not the fat accumulation by itself, produces cirrhosis. - Heribert Thaler, 1975 Triglyceride accumulation in the form of lipid droplets in the liver is likely an innocent bystander Clin Gastro 1975;4: Hepatology 2010;52:774-88
5 Lipotoxicity Model of Pathogenesis Our understanding of what causes NASH at the molecular level is still nascent Lipotoxicity Model of Pathogenesis Evidence now points to free fatty acids and their metabolites as the more substantial culprits in NASH pathogenesis Free fatty acids and their metabolites are highly toxic to cells Inflammation, Apoptosis, Necrosis, ER Stress Triglyceride accumulation as lipid droplets in the liver is a parallel phenomenon May serve as a non-toxic, safer form of storage for lipids in the liver Lipotoxicity Model of NAFLD Supply Disposal Neuschwander-Tetri, Hepatology 2010
6 Lipotoxicity Model of NAFLD Supply RED ARROWS indicate processes that contribute to the flux of FFA to the hepatocytes. Disposal Promote lipotoxic injury. Lipotoxicity Model of NAFLD Supply RED ARROWS indicate processes that contribute to the flux of FFA to the hepatocytes. Disposal Promote lipotoxic injury. Lipotoxicity Model of NAFLD Supply Disposal GREEN ARROWS indicate processes that eliminate FFA. Reduce lipotoxic injury.
7 Lipotoxicity Model of NAFLD Supply Disposal GREEN ARROWS indicate processes that eliminate FFA. Reduce lipotoxic injury. Lipotoxicity Model of NAFLD Supply Disposal No direct pathway from Steatosis to NASH Neuschwander-Tetri, Hepatology 2010 Lipotoxicity Model of NAFLD Free Fatty Acids and their metabolites are highly toxic to tissues Accumulation of TG is not needed for the development of NASH TG accumulation may, in fact, be protective Supply Steatosis does not progress to NASH Disposal Neuschwander-Tetri, Hepatology 2010
8 Magnitude of the Problem: NAFLD Prevalence Study cohort (~1100 African Americans, 700 Caucasians, 400 Hispanics) No risk factors (n = 375) H 1 -NMR spectroscopy Assess risk factors for NAFLD Define normal liver fat content 5.5% Assess prevalence of increased liver fat (steatosis) in entire population & ethnic subgroups Hepatology 2004;40:1387 NAFLD Prevalence: Dallas Heart Study Liver fat < 5.5% Liver fat > 5.5% Steatosis = 34% Hepatology 2004;40:1387 NAFLD Prevalence: Dallas Heart Study Liver enzymes NORMAL in most (79%) with steatosis Liver fat < 5.5% Liver fat > 5.5% Steatosis = 34% Hepatology 2004;40:1387
9 NAFLD AND NASH PREVALENCE IN US COHORT HIGHER THAN PREVIOUSLY ESTIMATED Williams CD, Stengel J, Asike MI, et al. Prevalence of NAFLD and NASH in a Largely Middle-aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study Gastroenterology. 2011;140: Summary of Study Design Primary Care outpatients (18-70 yo) at Brooke Army Medical Center, January March 2010 Excluded patients with known liver disease and alcohol use Right upper quadrant ultrasound reviewed for presence of steatosis based on echogenic features Laboratory analyses and percutaneous liver biopsy for patients identified as having fatty liver by ultrasound Williams CD, et al. Gastroenterology. 2011;140: Steatosis and NASH are Prevalent 46% of patients had NAFLD according to evidence from ultrasound and liver biopsy (if performed) Highest prevalence of NAFLD observed in Hispanics (58%), followed by Caucasians (44%) and lowest prevalence in African Americans (35%) 12% of all patients had NASH on liver biopsy All individuals with NASH were obese and hypertensive 74% of diabetics had NAFLD and 22% had NASH Several studies have documented a high prevalence of NAFLD with DM: 40-70% DM have 80% more hepatic fat compared with age-, weight- and sex-matched controls Williams CD, et al. Gastroenterology. 2011;140:
10 NASH is associated with the Number of Metabolic Derangements Dixon et al, Gastroenterology, 2001; 121: NAFLD High-Risk: Bariatric Surgery Patients Liver disease often unsuspected pre-operatively Intraoperative liver biopsy typically shows NAFLD (84-96%) Steatosis: 30-90% Steatohepatitis: 33-42% Fibrosis: Mild-to-Moderate Fibrosis: 33% Advanced Fibrosis: 12% Cirrhosis: 1-2% NAFLD High-Risk: Bariatric Surgery Patients Liver disease often unsuspected pre-operatively Intraoperative liver biopsy typically shows NAFLD (84-96%) Steatosis: 30-90% Steatohepatitis: 33-42% Fibrosis: Mild-to-Moderate Fibrosis: 33% Advanced Fibrosis: 12% Cirrhosis: 1-2% Advanced fibrosis ~14%
11 Hypercholesterolemia (55%) NAFLD High-Risk: Hyperlipidemia Adult Lipid Clinic Patients (n= 95) Hypertriglyceridemia (30%) Mixed dyslipidemia (15%) Dig Dis Sci 2000;45: Hypercholesterolemia (55%) NAFLD High-Risk: Hyperlipidemia Adult Lipid Clinic Patients (n= 95) Hypertriglyceridemia (30%) Mixed dyslipidemia (15%) Prevalence of NAFLD of = 50% Hypertriglyceridemia, mixed dyslipidemia risk 5-fold Dig Dis Sci 2000;45: NAFLD Increases with Increasing Age NAFLD occurs in all age groups Among adults, the prevalence of NAFLD increases with increasing age Prevalence of biopsy-proven NAFLD in traffic accident victims: 1% : < 20 years old 18% : years old 35% : 60 + years old Hilden et al. Scan J Gastro 1977; 12:593
12 NAFLD and Ethnicity/Race Different groups of individuals appear to be differentially affected by NAFLD NAFLD and Ethnicity/Race Different groups of individuals appear to be differentially affected by NAFLD Given the high prevalence of obesity and DM among African Americans NAFLD and Ethnicity/Race Different groups of individuals appear to be differentially affected by NAFLD Given the high prevalence of obesity and DM among African Americans Postulate that NAFLD should be more prevalent among this population
13 NAFLD and Ethnicity/Race Different groups of individuals appear to be differentially affected by NAFLD Given the high prevalence of obesity and DM among African Americans Postulate that NAFLD should be more prevalent among this population However, several studies have demonstrated the contrary Prevalence of Hepatic Steatosis Varies with Ethnicity and Race Fatty liver Prevalence (%) Dallas Heart Study Use of NMR to assess hepatic triglyceride content Population-based sample Hepatic Steatosis and Race/Ethnicity Fatty liver Prevalence (%) 45% Latino
14 Hepatic Steatosis and Race/Ethnicity Fatty liver Prevalence (%) 45% Latino 33% Caucasian Hepatic Steatosis and Race/Ethnicity Fatty liver Prevalence (%) 45% 33% 24% Latino Caucasian African American Hepatic Steatosis and Race/Ethnicity Fatty liver Prevalence (%) Median Hepatic Triglyceride Content 4.6% 45% Latino 3.6% 33% Caucasian 3.2% 24% African American
15 Hepatic Steatosis and Race/Ethnicity Fatty liver Prevalence (%) Median Hepatic Triglyceride Content 4.6% 45% Latino 3.6% 33% Caucasian 3.2% 24% African American Hepatic Steatosis and Race/Ethnicity Differences in hepatic triglyceride content were not explained by total, subcutaneous abdominal or lower extremity fat Intraperitoneal fat accounted for the majority of variation in hepatic triglyceride content among race/ethnic groups Hepatology 2009;49:791 Hepatic Steatosis and Race/Ethnicity Differences in hepatic triglyceride content were not explained by total, subcutaneous abdominal or lower extremity fat Intraperitoneal fat accounted for the majority of variation in hepatic triglyceride content among race/ethnic groups Very close association between intraperitoneal fat and liver fat, regardless of race/ethnicity Hepatology 2009;49:791
16 Genetics of NAFLD GWAS of NAFLD patients Identified rs738409, a SNP within PNPLA3 gene (patatin-like phopholipase domain-containing) Adiponutrin: highly expressed in liver and adipose, but exact role not fully understood Strongly associated with hepatic fat content Romeo, S. et al. Nat. Genet. 40, (2008) PNPLA3 SNP Hepatic fat content highest for GG homozygotes (2x higher than non-carriers) G allele: Most common in Hispanic individuals Intermediate frequency in Caucasians Lowest frequency in African Americans PNPLA3 SNP is also associated with increased necroinflammation and fibrosis in NASH Romeo, S. et al. Nat. Genet. 40, (2008) Natural History of NAFLD: Dependent on Histology Natural history depends upon the histologic subtype of NAFLD Simple Steatosis generally benign prognosis NASH may develop fibrosis leading to cirrhosis
17 Natural History of NAFLD Study of NAFLD outcomes in a community-based, outpatient population in Olmsted County, MN Diagnosis of NAFLD (n=435) Liver biopsy Hepatic imaging consistent with fatty liver Exclusion of other causes of liver disease and excessive alcohol use Median follow-up time = 7.6 years Adams et al. Gastro 2005;129:113 NAFLD Increases Mortality Significantly lower survival in NAFLD compared with general population NASH Histology Increases Mortality Risk No patients with simple steatosis died during follow-up 35% of patients with NASH died during follow-up Adams et al. Gastro 2005;129:113
18 Adams et al. Gastro # 1 # 2 # 3 Adams et al. Gastro Risk Factors for Fibrosis/Cirrhosis Obesity Age > Diabetes Hypertension Smoking Fructose Intake Fast Food Consumption Sedentary Lifestyle
19 Risk Factors for Fibrosis/Cirrhosis Obesity Age > Diabetes Hypertension Smoking Fructose Intake Fast Food Consumption Sedentary Lifestyle 66% prevalence of advanced hepatic fibrosis if: Age > 50 and Obese and DM NASH-Cirrhosis: Increases Mortality and HCC Risk Child Class A Cirrhosis Sanyal et al, Hepatology 2006, 43: NAFLD and Cardiovascular Disease Overall, the available evidence demonstrates: Patients with NAFLD have multiple risk factors for CVD Patients with NASH (compared with simple steatosis): 3-fold increased incidence of cardiovascular disease 2-fold increase in cardiovascular mortality
20 NAFLD and Cardiovascular Disease Overall, the available evidence demonstrates: Patients with NAFLD have multiple risk factors for CVD Patients with NASH (compared with simple steatosis): 3-fold increased incidence of cardiovascular disease 2-fold increase in cardiovascular mortality CVD is much more common than liver disease as a cause of death, especially with NASH The association between NAFLD and CVD is independent of diabetes status Who are NAFLD Suspects? Who are NAFLD Suspects?
21 Who are NAFLD Suspects? Who are NAFLD Suspects? Lab Evaluation for NAFLD No specific, widely available serologic markers for distinguishing NASH from Simple Steatosis
22 Promising Biochemical Marker for NASH: CK 18 Cytokeratin 18 (CK 18) Fragments Measure of apoptosis Hepatocyte apoptosis is a key pathway of liver injury and cell death in NASH Hepatocyte apoptosis NASH >> Simple Steatosis Promising Biochemical Marker for NASH: CK 18 Cytokeratin 18 (CK 18) Fragments Measure of apoptosis Hepatocyte apoptosis is a key pathway of liver injury and cell death in NASH Hepatocyte apoptosis NASH >> Simple Steatosis CK 18 fragments NASH >> Simple Steatosis Very promising test, but not yet routinely available Assess Severity of Liver Disease: Looking for NASH and Fibrosis Liver Biopsy = Gold standard Important component of the evaluation for NAFLD Necessary to definitively diagnose NASH Limitations: Sampling error Invasive Expense
23 Assess Severity of Liver Disease: Fibrosis To restrict the large number of potential candidates with suspected NAFLD for liver biopsy, several non-invasive surrogate markers of fibrosis have been investigated NASH Fibrosis Score FIB 4 AST/ALT BARD In clinical practice these scores may reduce the proportion of patients undergoing liver biopsy to diagnose mild disease Management Options: Targeting Metabolic Derangements NAFLD severity is associated with metabolic comorbidities Manage (prevent) metabolic derangements Typical therapies for metabolic disorders are generally safe in patients with NAFLD Rationale for Therapeutics for NASH Insulin sensitizers Insulin resistance FFA + insulin+ cytokines metabolic dysregulation ER stress Oxidative stress Mitochondrial injury Anti oxidants Nuclear Transcription Factors and AMP-activated protein kinase (AMPK) represent novel targets for NAFLD Inflammatory signaling Stellate cell activation fibrosis Apoptosis Cell death Vitamin E: Lipophylic anti-oxidant; blocks propagation of lipid peroxidation
24 Management Options: Therapy Specific for NAFLD BENEFICIAL Insulin sensitizers : TZDs Vitamin E : PIVENS Trial Weight Loss (+/- Bariatric Surgery) Management Options: Therapy Specific for NAFLD BENEFICIAL Insulin sensitizers : TZDs Vitamin E : PIVENS Trial Weight Loss (+/- Bariatric Surgery) STILL UNPROVEN Lipid lowering agents: Statins, fibrates Metformin Other Antioxidants: Betaine, SAMe Probiotics Insulin secretagogues TNF-alpha inhibitors (Pentoxifylline) Milk Thistle Management Options: Therapy Specific for NAFLD BENEFICIAL Insulin sensitizers : TZDs Vitamin E : PIVENS Trial Weight Loss (+/- Bariatric Surgery) STILL UNPROVEN Lipid lowering agents: Statins, fibrates Metformin Other Antioxidants: Betaine, SAMe Probiotics Insulin secretagogues TNF-alpha inhibitors (Pentoxifylline) Milk Thistle NOT BENEFICIAL Ursodeoxycholic acid
25 PIVENS CLINICAL TRIAL: PIOGLITAZONE, VITAMIN E, OR PLACEBO FOR NASH Sanyal AJ, Chalasani N, Kowdley KV, et al. For the NASH Clinical Research Network Vitamin E is Superior to Placebo for Improving NASH in Nondiabetic Patients NEJM 2010; 362: 1675 PIVENS Vitamin E vs. Pioglitazone vs. Placebo Wk 96 Nondiabetic patients with NASH (N = 247) Vitamin E 800 IU QD + Pioglitazone-like Placebo (n = 84) Pioglitazone 30 mg QD + Vitamin E-like Placebo (n = 80) Pioglitazone- + Vitamin E-like Placebos QD (n = 83) Sanyal AJ, et al. N Engl J Med. 2010;362: Vitamin E Improves NASH Vitamin E, but not pioglitazone, resulted in significant overall histologic improvement in NASH at Wk 96 when compared with placebo (p <.025) NNT with vitamin E to achieve histologic improvement in 1 patient: % of patients showed histologic improvement with Vitamin E 57% non-responders Sanyal AJ, et al. N Engl J Med. 2010;362:
26 Vitamin E and Pioglitazone Improve Steatosis and Inflammation Significantly higher rates of improved steatosis and lobular inflammation with vitamin E and pioglitazone vs placebo Patients With Improvement (%) P = P < Steatosis P = P < Lobular Inflammation P = P = Hepatocellular Ballooning P =.24 P = Fibrosis Vitamin E Pioglitazone Placebo Sanyal AJ, et al. N Engl J Med. 2010;362: PIVENS Pioglitazone associated with significant improvement in insulin resistance but also significant weight gain (5.5kg) Changes observed by Wk 24 Weight gain progressed out to Wk 96 After cessation of Pioglitazone: Insulin resistance returned to baseline Weight gain persisted Sanyal AJ, et al. N Engl J Med. 2010;362: Vitamin E: Caveats High Dose Vitamin E Supplementation May Increase All- Cause Mortality Significant association between dose of Vitamin E and all-cause mortality Vitamin E is associated with HR 1.17 for prostate cancer (p=0.008) Annals of Internal Medicine 2005 JAMA 2011
27 Additional Management Options for NAFLD Weight loss (at least 7%) Gastric Bypass Surgery Reduce steatosis, generally beneficial for steatohepatitis, inconsistent in fibrosis Dietary Changes Decrease fructose consumption, saturated fats, simple carbohydrates and trans fats Increased fructose consumption (>7 servings/week) is associated with increased fibrosis, inflammation and ballooning in NAFLD patients Increase PUFAs and Omega 3 FA Additional Management Options for NAFLD Increase physical activity Improvement in cardiorespiratory fitness, even in absence of weight loss, has been shown to improve NASH histology Abnormal Liver Tests or Liver Imaging, metabolic features Assess clinical risk factors for having NASH +/- fibrosis to categorize the degree of risk Consider Vitamin E Clinical Trials
28 Key Concepts for NAFLD 1. NAFLD is very prevalent among U.S. adults, affecting up to 46% of individuals Especially prevalent among patients with diabetes, affecting 40-70% 2. NASH is the more aggressive form of NAFLD 6-13% of the U.S. adult population 3. Liver biopsy is still necessary to distinguish between simple steatosis and NASH 4. NASH can, and does, occur in the setting of normal aminotransferases (~20% of cases) 5. Risk factors for fibrosis in NAFLD include: Age > years, Diabetes, Obesity, HTN, Smoking, Fructose consumption, Fast Food Consumption, Sedentary lifestyle Key Concepts for NAFLD 6. NASH is associated with reduced survival compared with the general population (top 3 causes of death with NAFLD: #1: Malignancy; #2: Ischemic Heart Disease; #3: Liver Disease) 7. Aerobic activity, dietary modification and weight loss are associated with improvements in NASH. Vitamin E is a therapeutic option for selected patients with NASH 8. Though commonly used, metformin has not been shown to consistently improve NASH histology. Though patients frequently ask about it, there is no data suggesting that milk thistle is beneficial for NASH 9. No FDA approved specific medications for NASH, but numerous clinical trials utilizing novel agents are in progress, capitalizing on the emerging data on NAFLD pathogenesis
NONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012
NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD Simple Steatosis Fatty hepatocytes Intracellular fat
More informationPREVALENCE OF NAFLD & NASH
- - PREVALENCE OF & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology 2011; 140:124-31) Dallas Heart Study Prevalence Numbers (Browning et al., Hepatology 2004;40:1387-95)
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
More informationNon-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease None Disclosures Arslan Kahloon M.D Chief, Division of Gastroenterology and Hepatology University of Tennessee College of Medicine Chattanooga Objectives Understand the
More informationImproving Access to Quality Medical Care Webinar Series
Improving Access to Quality Medical Care Webinar Series Presented by The Arizona Telemedicine Program and the Southwest Telehealth Resource Center 2015 UA Board of Regents Welcome AZ, UT, CO, NM & NV FLEX
More informationEarly life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016.
Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016. Outline Definition NAFLD and NASH Magnitude of the problem
More informationPEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE
PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE Updates on New insights into NAFLD and NASH pathophysiology New AASLD/AGA/ACG guidelines for NAFLD and NASH, as pertains to pediatrics Evidence-based
More informationWHAT CAN YOU USE IN YOUR CLINIC TODAY FOR THE TREATMENT OF NASH?
WHAT CAN YOU USE IN YOUR CLINIC TODAY FOR THE TREATMENT OF NASH? Helena Cortez-Pinto Laboratório de Nutrição, FML, Serviço de Gastrenterologia, Hospital St Maria, Lisboa, Portugal EASL Governing Board:
More informationFatty liver disease: What do we know?
Fatty liver disease: What do we know? Prof. Dr. Claus Niederau Katholische Kliniken Oberhausen ggmbh St. Josef-Hospital Academic Teaching Hospital University of Duisburg-Essen NAFLD Non-Alcoholic Fatty
More informationNAFLD: US GUIDELINES. US Guidelines for NAFLD
NAFLD: US GUIDELINES Arun J Sanyal M.D. Charles Caravati Professor of Medicine Virginia Commonwealth University School of Medicine US Guidelines for NAFLD Represents consensus amongst AGA, AASLD and ACG
More informationNAFLD & NASH. Naga Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology
NAFLD & NASH Naga Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology Indiana University School of Medicine ACG Midwest Regional Course,
More informationDietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and
Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and Dietetics Tehran University of Medical Sciences Honorary Academic
More informationNAFLD/NASH in Sub- Saharan Africa
NAFLD/NASH in Sub- Saharan Africa Corné Kruger Gastroenterologist Durbanville Mediclinic Cape Town Liver Interest group meeting: Cape Town 2015 Introduction NAFLD is the most common liver disease disease
More informationNASH PROGRESS IN THE LAST DECADE
PROGRESS IN THE LAST DECADE Mitchell L. Shiffman, MD, FACG Director Health System Richmond and Newport News, VA Medical Group Good Help to Those in Need A GLOBAL HEALTH PROBLEM Nigeria Australia Spain
More informationNON-ALCOHOLIC FATTY LIVER DISEASE:
NON-ALCOHOLIC FATTY LIVER DISEASE: ROLE OF THE PRIMARY PROVIDER Archita P. Desai, MD Assistant Professor of Medicine University of Arizona 25 th Annual Southwestern Conference on Medicine Outline Pathophysiology
More informationFATTY LIVER DISEASE (NAFLD) (NASH) A GROWING
NON ALCOHOLIC FATTY LIVER DISEASE () & NON ALCOHOLIC S T E ATO H E PAT I T I S () ADDRESSING A GROWING SILENT EPIDEMIC Prevalence of & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams
More informationDiseases to Watch. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic
Diseases to Watch Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic steatohepatitis (NASH) - Prevalence and Symptoms - Risk Factors and Potential treatments - Target identification for NASH Robert
More informationUpdate on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI
Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none
More informationWhat is NAFLD?.NASH? Presenter Disclosure Information. Learning Objectives. Case 1: Rob. Questions Pertinent to Rob
Presenter Disclosure Information 5 6pm Nonalcoholic Fatty Liver Disease (NAFLD): Another Obesity-Related Epidemic SPEAKER Elliot Tapper, MD The following relationships exist related to this presentation:
More informationUpdate on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic
Update on Nonalcoholic Fatty Liver Disease Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic Outline Defining the phenotypes of nonalcoholic fatty liver disease NAFLD Diagnostics
More informationCDHNF & NASPGHAN A Partnership for Research and Education for Children s Digestive and Nutritional Health
CDHNF & NASPGHAN A Partnership for Research and Education for Children s Digestive and Nutritional Health Obesity and NAFLD Definitions: Nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver
More informationNAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology
NAFLD/NASH Vicki Shah PA-C, MMS Rush University Hepatology Definitions NAFLD Evidence of hepatic steatosis by histology (5%) or imaging No causes for secondary fat accumulation EtOH, Drugs, hereditary
More informationThe Skinny On Non Alcoholic Fatty Liver Disease
The Skinny On Non Alcoholic Fatty Liver Disease UCSF Advances in Internal Medicine Monika Sarkar, MD, MAS UCSF Division of GI/Hepatology June 24th, 2015 Non Alcoholic Fatty Liver Disease: Outline Pathogenesis
More informationInternal Medicine Grand Rounds University of Texas Southwestern Medical Center October 5, 2018
Internal Medicine Grand Rounds University of Texas Southwestern Medical Center October 5, 2018 Nonalcoholic Fatty Liver Disease (NAFLD) Turns 38-What Have We Learned? Jay D. Horton, M.D. This is to acknowledge
More informationMETABOLIC SYNDROME AND HCV: FROM HCV
METABOLIC SYNDROME AND HCV: FROM THEORY TO PRACTICE HCV Steatosis Insulin resistance Arun J Sanyal M.D. Chairman, Div. of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University Richmond,
More informationNAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain
NAFLD: evidence-based management Curso de residentes AEEH 2017 Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain Clinical case - 55 yo female - Sent for incidental steatosis at abdominal
More informationFatty Liver Disease. Mark Thursz. Imperial College
Fatty Liver Disease Mark Thursz Imperial College Non-Alcoholic Fatty Liver Disease UK adult obesity (BMI>30) 1980: 6% [M], 8% [F]. 1997: 17% [M], 20% [F]. By 2004, 23.6% of men and 23.8% of women were
More informationAAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease
AAIM: GI Workshop Follow Up to Case Studies Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease Daniel Zimmerman, MD VP and Medical Director, RGA Global October 2015 Non-alcoholic Fatty
More informationFatty Liver Disease A growing epidemic
Fatty Liver Disease A growing epidemic Updates in GIM for Primary Care Don C. Rockey March 9 th, 2018 Disclosures 2018 Research Funding (all to MUSC) NIH/NIDDK Actelion Pharmaceuticals Gilead Sciences
More informationFatty Liver- how important is it? Jeremy F.L. Cobbold MA PhD MRCP Clinical Lecturer in Hepatology Imperial College London
Fatty Liver- how important is it? Jeremy F.L. Cobbold MA PhD MRCP Clinical Lecturer in Hepatology Imperial College London Fatty liver- how important is it? Importance in terms of: Prevalence Pathogenesis
More informationNon-Alcoholic Steatohepatitis (NASH): What the Gastroenterologist Should Know
Non-Alcoholic Steatohepatitis (NASH): What the Gastroenterologist Should Know Naga P. Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology
More informationNAFLD & NASH: Russian perspective
NAFLD & NASH: Russian perspective Vasily Isakov, MD, PhD Professor, Chief, Department Gastroenterology & Hepatology, Federal Research Center of nutrition, biotechnology and food safety Disclosures Received
More informationDisclosure. Objectives. Smash the Nash: A practical approach to fatty liver disease
Smash the Nash: A practical approach to fatty liver disease Bruce D. Askey, MS, ANP-BC Associate Lecturer North Andover, MA Adult Nurse Practitioner Dept. of Hepatology/Gastroenterology Guthrie Clinic
More informationLaboratory analysis of the obese child recommendations and discussion. MacKenzi Hillard May 4, 2011
Laboratory analysis of the obese child recommendations and discussion MacKenzi Hillard May 4, 2011 aka: What to do with Fasting Labs The Obesity Epidemic The prevalence of obesity in adolescents has tripled
More informationPrognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014
Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014 Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France NASH : a severe hepatic
More informationtage Percent Total & over Total & over Men Women Men Women
Paul Angulo, MD, FACG, AGAF Professor of Medicine, Section Chief of Hepatology Division i i of Digestive i Diseases and Nutrition i University of Kentucky Medical Center Lexington, KY Paul Angulo, MD University
More information[Sem Liver Disease 21(1):81-88, Thieme Medical Publishers, Inc.]
Treatment of Nonalcoholic Fatty Liver: Present and Emerging Therapies [Sem Liver Disease 21(1):81-88, 2001. 2001 Thieme Medical Publishers, Inc.] Paul Angulo, M.D., and Keith D. Lindor, M.D., Division
More informationReview Article A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD
Gastroenterology Research and Practice Volume 2016, Article ID 7109270, 17 pages http://dx.doi.org/10.1155/2016/7109270 Review Article A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical
More informationNon-Alcoholic Fatty Liver Diseasean underestimated epidemic
Non-Alcoholic Fatty Liver Diseasean underestimated epidemic Amir Shlomai MD,PhD Head, Department of Medicine D The Liver Institute Rabin Medical Center, Beilinson Hospital The IASLD semi-annual meeting-
More informationWhat to do about the high ALT picked up at the annual review. Dr Michael Yee Consultant in Diabetes and Endocrinology
What to do about the high ALT picked up at the annual review Dr Michael Yee Consultant in Diabetes and Endocrinology Mrs DC HPC PMH Type 2 Diabetes (decades) Regular retinal screening No foot complications/neuropathy
More informationNON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES
NON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES Preface Zobair M. Younossi xiii Epidemiology and Natural History of NAFLD and NASH 1 Janus P. Ong and Zobair M. Younossi Understanding
More informationNon-Alcoholic Fatty Liver Disease (NAFLD)
HEPATO-PANCREATO-BILIARY STOMACH CANCER PROGRAM Non-Alcoholic Fatty Liver Disease (NAFLD) Steatosis and Non-Alcoholic Steatohepatitis (NASH) Management Recommendations UCSF Fresno Department of Surgery
More informationNon-alcoholic fatty liver disease: time to take note and manage. Philip Newsome Professor of Hepatology & Director of Centre for Liver Research
Non-alcoholic fatty liver disease: time to take note and manage Philip Newsome Professor of Hepatology & Director of Centre for Liver Research Disclosures Consultancy, Co-ordinating Investigator roles
More informationLiver Pathology in the 0bese
Liver Pathology in the 0bese Rob Goldin Centre for Pathology, Imperial College r.goldin@imperial.ac.uk Ludwig et al. Non-alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.
More informationUpdate on Clinical Management
Non-Alcoholic Fatty Liver Disease Update on Clinical Management Lisa J. Yoo, D.O. Gastroenterologist Regional Gastroenterology INTRODUCTION Non-alcoholic fatty liver disease (NAFLD) is characterized by
More informationTherapeutic targets and the management of NASH
Therapeutic targets and the management of NASH Joo Hyun Sohn, MD. Professor of Medicine, College of Medicine, Hanyang University Division of Gastroenterology and Hepatology Hanyang University Guri Hospital
More informationNonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup
REVIEW REVIEW Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup Puneet Puri, M.B.B.S., M.D. and Arun J. Sanyal, M.B.B.S., M.D. Nonalcoholic fatty liver disease (NAFLD) is defined
More informationNormal ALT for men 30 IU/L 36% US males abnormal. Abnl ALT. Assess alcohol use/meds. Recheck in 6-8 weeks. still pos
Fatty liver disease Its not just for big boys anymore Ken Flora, MD, FAASLD, FACG, AGAF No disclosures Common situation Normal ALT for men 30 IU/L 36% US males abnormal Normal ALT for women 20 IU/L 28%
More informationNAFLD: ACG Southern Regional Course Nashville, TN. Speaking - None
NAFLD: 2015 Naga Chalasani, MD, FACG David W. Crabb Professor of Medicine Director, Division of GI and Hepatology Indiana University School of Medicine ACG Southern Regional Course Nashville, TN Disclosures
More informationNASH: WHAT YOU NEED TO KNOW
NASH: WHAT YOU NEED TO KNOW MARCELO KUGELMAS, MD, FACP SOUTH DENVER GASTROENTEROLOGY CENTER FOR DISEASES OF THE LIVER AND PANCREAS, SWEDISH MEDICAL CENTER CLINICAL ASSOCIATE PROFESSOR OF MEDICINE, UNIVERSITY
More informationConflicts of Interest in the last 12 months
STEATOHEPATITIS Richard K. Sterling, MD, MSc, FACP, FACG VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Richmond, VA Conflicts of Interest in the last
More informationNew targets for the treatment of NASH (NAFLD) in 2012?
New targets for the treatment of NASH (NAFLD) in 2012? Dominique Larrey Service d Hépatogastroenterologie et transplantation Hôpital Saint Eloi CHU Montpellier INSERM 1040-IRB France Dom-larrey@chu-montpellier.fr
More informationFast-food, Fatty liver, & Insulin Resistance. Giulio Marchesini Clinical Dietetics Alma Mater Studiorum University of Bologna
Fast-food, Fatty liver, & Insulin Resistance Giulio Marchesini Clinical Dietetics Alma Mater Studiorum University of Bologna Supersize Me Unhealthy Effects of Fast Food After consuming three meals a day
More informationPreface: Nonalcoholic Fatty Liver Disease: An Expanding Health Care Epidemic
NASH and NAFLD Preface: Nonalcoholic Fatty Liver Disease: An Expanding Health Care Epidemic David E. Bernstein xiii Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
More informationNonalcoholic Fatty Liver Disease in Children: Typical and Atypical
Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical Disclosure Naim Alkhouri, MD discloses the following relationships with commercial companies: Membership in the Speakers Bureau for Alexion
More informationFatty Liver in HIV. Richard K. Sterling, MD, MSc, FACP, FACG
Fatty Liver in HIV Richard K. Sterling, MD, MSc, FACP, FACG Professor of Medicine Chief, Section of Hepatology Director, HIV-Liver Disease Virginia Commonwealth University Liver-Related Deaths in HIV 1246
More informationNAFLD AND TYPE 2 DIABETES
NAFLD AND TYPE 2 DIABETES Sonia Caprio, MD STOPNASH Symposium on the Origin and Pathways of Nonalcoholic Steatohepatitis Washington 7, 215 Global Projection of Diabetes Hossain P et al. N Engl J Med 27;356:213
More informationPrevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar
Original Research Article Prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar Naresh Kumar 1, Jyoti Kumar Dinkar 2*, Chandrakishore
More informationAt Least 1 in 5 Patients in Your Practice Have Fatty Liver
At Least 1 in 5 Patients in Your Practice Have Fatty Liver What Can You Tell Your Patients Magnus McLeod MD FRCPC Assistant Professor Dalhousie University 30-NOV-2017 NAFLD Non-Alcoholic Fatty Liver Disease
More informationNASH UPDATE ON DIAGNOSTICS AND THERAPY. Arun J Sanyal MBBS, MD Virginia Commonwealth University School of Medicine
NASH UPDATE ON DIAGNOSTICS AND THERAPY Arun J Sanyal MBBS, MD Virginia Commonwealth University School of Medicine Conflicts of interest Salaried employee: of VCU Member of Board: McGuire VA Research Institute,
More informationNASH Bench to Bedside
NASH Bench to Bedside October 2006 Anna Mae Diehl, M.D. Gastroenterology Division Duke University NonAlcoholic Fatty Liver Disease Common ~1/4-1/3 1/3 US adults Outcome highly variable Course indolent
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abetalipoproteinemia NASH and, 537 Acquired errors of metabolism NASH and, 536 537 Amiodarone steatohepatitis due to, 527 Anticonvulsant mood
More informationNon alcoholic fatty liver and Non alcoholic Steatohepatitis. By Dr. Seham Seif
Non alcoholic fatty liver and Non alcoholic Steatohepatitis By Dr. Seham Seif Definition NAFL describe a common clinicopathological conditions characterized by significant lipid deposition in the hepatocytes
More informationNAFLD - therapeutic intervention. CP Day Institute of Cellular Medicine Newcastle University UK
NAFLD - therapeutic intervention CP Day Institute of Cellular Medicine Newcastle University UK Therapy for NAFLD Why worry about NAFLD? Management strategy - who to treat? Therapies directed at features
More informationLavine, MD, PhD; 4 Anna Mae Diehl, MD; 5 Elizabeth M. Brunt, MD; 6 Kenneth Cusi, MD; 7 Michael Charlton, MD; 8 Arun J. Sanyal, MD
Page 1 of 59 The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and
More informationUniversity of Groningen. Non-alcoholic fatty liver disease Sheedfar, Fareeba
University of Groningen Non-alcoholic fatty liver disease Sheedfar, Fareeba IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationMetabolic Syndrome. DOPE amines COGS 163
Metabolic Syndrome DOPE amines COGS 163 Overview - M etabolic Syndrome - General definition and criteria - Importance of diagnosis - Glucose Homeostasis - Type 2 Diabetes Mellitus - Insulin Resistance
More informationUMHS-PUHSC JOINT INSTITUTE
Role of Visceral Adiposity in the Pathogenesis of Non-Alcoholic Fatty Liver Disease in Lean versus Obese Patients: A Comparative Study between Patients at UMHS versus PUHSC Lai WEI and Anna LOK W Zhang,
More informationChewing the Fat on Fatty Liver Mike Kolber MD, CCFP, MSc PEIP 2018
Chewing the Fat on Fatty Liver Mike Kolber MD, CCFP, MSc PEIP 2018 Faculty/Presenter Disclosure Faculty: Michael Kolber Relationships with financial sponsors: Grants/Research Support: Alberta College of
More informationEVALUATION OF ABNORMAL LIVER TESTS
EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical
More informationInvestigating general liver disease/transaminitis
BHIVA Autumn Conference London 14 October 2016 Investigating general liver disease/transaminitis Emmanuel A. Tsochatzis Senior Clinical Lecturer and Consultant Hepatologist Institute for Liver and Digestive
More informationAssessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 6 Ver. IV (June. 2017), PP 49-53 www.iosrjournals.org Assessment of Liver Stiffness by Transient
More informationNon alcoholic fatty liver disease and atherosclerosis Raul Santos, MD
Non alcoholic fatty liver disease and atherosclerosis Raul Santos, MD Sao Paulo Medical School Hospital Sao Paulo, Brazil Disclosure Honoraria received for consult and/or speaker : Astra Zeneca, Amgen,
More informationEASL EASD EASO Clinical practice guidelines for the management of nonalcoholic fatty liver disease.
Commentary. EASL EASD EASO Clinical practice guidelines for the management of nonalcoholic fatty liver disease. Christopher D. Byrne 1,2, Giovanni Targher 3 1 Nutrition and Metabolism, Faculty of Medicine,
More informationNICE guideline Published: 6 July 2016 nice.org.uk/guidance/ng49
Non-alcoholic fatty liver disease (NAFLD): assessment and management NICE guideline Published: 6 July 20 nice.org.uk/guidance/ng49 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationM30 Apoptosense ELISA. A biomarker assay for detection and screening of NASH
M30 Apoptosense ELISA A biomarker assay for detection and screening of NASH NASH A Global Disease In the Western countries, Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common liver disease, strongly
More informationThe Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Update 2013 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine Denver Health
More informationEmerging Challenges in Primary Care: Non-Alcoholic SteatoHepatitis (NASH): Identification & Evolving Treatment Strategies
Emerging Challenges in Primary Care: 2016 Non-Alcoholic SteatoHepatitis (NASH): Identification & Evolving Treatment Strategies Faculty Kalyan R. Bhamidimarri, MD, MPH Assistant Professor/ Transplant Hepatology
More informationPatient Information Leaflet Non-Alcoholic Fatty Liver Disease (NAFLD) fatty-liver
Patient Information Leaflet Non-Alcoholic Fatty Liver Disease (NAFLD) fatty-liver Derriford Hospital Derriford Road Plymouth PL6 8DH Tel: 01752 431320 www.plymouthhospitals.nhs.uk 1 What is fatty liver?
More informationEvercore ISI Presentation- Madrigal
Evercore ISI Presentation- Madrigal Forward-Looking Statements Any statements, other than statements of historical facts, made in this presentation regarding our clinical studies and our research and development
More informationIn Search of New Biomarkers for Nonalcoholic Fatty Liver Disease
REVIEW In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease Ting-Ting Chan, M.R.C.P., and Vincent Wai-Sun Wong, M.D. Nonalcoholic fatty liver disease (NAFLD) affects 15% to 40% of the general
More informationWHAT THE EXPERIMENTAL MODELS CAN TEACH US IN NAFLD/NASH? Claudio Tiribelli, MD PhD Scientific Director FIF
WHAT THE EXPERIMENTAL MODELS CAN TEACH US IN NAFLD/NASH? Claudio Tiribelli, MD PhD Scientific Director FIF ctliver@fegato.it Worldwide estimated prevalence of NAFLD distribution of PNPLA3 genotypes 2017-Younussi
More informationLipoatrophic Diabetes: What can zebras teach us about horses? Ranganath Muniyappa, MD, PhD Diabetes, Endocrinology, and Obesity Branch NIDDK, NIH
Lipoatrophic Diabetes: What can zebras teach us about horses? Ranganath Muniyappa, MD, PhD Diabetes, Endocrinology, and Obesity Branch NIDDK, NIH Objectives 1. Describe the clinical manifestations of abnormal
More informationMetabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic
More information«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin
«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin OUTLINE NAFLD overview NAFLD and menarche NAFLD and pregnancy NAFLD and menopause Other metabolic
More informationEASL-EASD-EASO Clinical Practice Guidelines for the management and treatment of NAFLD. Francesco Negro University of Geneva - Switzerland
EASL-EASD-EASO Clinical Practice Guidelines for the management and treatment of NAFLD Francesco Negro University of Geneva - Switzerland EASL EASD - EASO G Marchesini CP Day J-F Dufour A Canbay V Nobili
More informationThe health risks associated with obesity are widespread and
GASTROENTEROLOGY 2012;142:711 725 IN BASIC CLINICAL GASTROENTEROLOGY HEPATOLOGY Robert F. Schwabe and John W. Wiley, Section Editors Role of Obesity and Lipotoxicity in the Development of Nonalcoholic
More informationNonalcoholic Steatohepatitis National Digestive Diseases Information Clearinghouse
Nonalcoholic Steatohepatitis National Digestive Diseases Information Clearinghouse National Institute of Diabetes and Digestive and Kidney Diseases NATIONAL INSTITUTES OF HEALTH Nonalcoholic steatohepatitis
More informationFatty Liver Disease OPSO Fall Conference 2018
Fatty Liver Disease OPSO Fall Conference 2018 Cynthia Worden, DO, MSHPE NAFLD Non-alcoholic fatty liver disease (NAFLD) is now considered to be the most common liver disease in the Western world and has
More informationModern view of non-alcoholic fatty liver disease Key words:
Modern view of non-alcoholic fatty liver disease T. O. Tanryberdieva, M. C. Beknepesova, V. A. Gurbanov, O. N. Agahanowa Turkmenistan State Medical University, Ashkhabad, Turkmenistan Key words: non-alcoholic
More informationLinda Ferrell, MD Distinguished Professor Vice Chair Director of Surgical Pathology Dept of Pathology
Linda Ferrell, MD Distinguished Professor Vice Chair Director of Surgical Pathology Dept of Pathology Nonalcoholic steatohepatitis and Fatty Liver Disease Liver manifestations of the obesity epidemic Changes
More informationNovel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis
Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis Alina M. Allen, Meng Yin, Sudhakar K. Venkatesh, Taofic Mounajjed, Todd A. Kellogg,
More informationMacrovascular Disease in Diabetes
Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based
More informationTreatment of NASH: What Helps Beyond Weight Loss?
THE RED SECTION 821 see related editorial on page x Treatment of NASH: What Helps Beyond Weight Loss? Bubu A. Banini, MD, PhD1 and Arun J. Sanyal, MBBS, MD1 Am J Gastroenterol 2017; 112:821 824; doi: 10.1038/ajg.2017.83;
More informationPre-diabetes. Pharmacological Approaches to Delay Progression to Diabetes
Pre-diabetes Pharmacological Approaches to Delay Progression to Diabetes Overview Definition of Pre-diabetes Risk Factors for Pre-diabetes Clinical practice guidelines for diabetes Management, including
More informationIL METABOLISMO EPATICO DEI CARBOIDRATI IN FISIOLOGIA E PATOLOGIA
UNIGASTRO Il fegato come centrale metabolica e i fattori di danno oltre ai virus epatitici IL METABOLISMO EPATICO DEI CARBOIDRATI IN FISIOLOGIA E PATOLOGIA Dr Elisabetta Bugianesi Divisione di Gastro-Epatologia
More informationEnd Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP-BC Introduction (https://www.srtr.org) What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
More informationEnd Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC Introduction (https://www.srtr.org) 1 What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
More informationNon-alcoholic fatty liver disease: when to intervene and with what
CME HEPATOLOGY Clinical Medicine 2015 Vol 15, No 2: 186 90 Non-alcoholic fatty liver disease: when to intervene and with what Authors: Nwe Ni Than A and Philip N Newsome B ABSTRACT Non-alcoholic fatty
More information